person · Reporting owner
Capone Mark Christopher
Disclosed activity across 4 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| DermTech, Inc.DMTK · Entity 89998 | Director | June 01, 2023 | June 05, 2023 |
| MESA LABORATORIES INC /CO/MLAB · Entity 5221 | Director | September 09, 2026 | September 11, 2026 |
| MYRIAD GENETICS INCMYGN · Entity 5953 | President & C.E.O. | September 30, 2019 | October 01, 2019 |
| SERA PROGNOSTICS, INC.SERA · Entity 304 | Director | July 10, 2026 | July 14, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
DermTech, Inc.
Report date June 01, 2023 · Filed June 05, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 82,054 |
Reported balance
After 2023-06-01 transaction · row 1
1 source rowRow 1 · 2023-06-01 · Grant · Acquired 35,714 · Balance 82,054 F1: The securities awarded are in the form of restricted stock units issued pursuant to the issuer's 2020 Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of issuer common stock. The restricted stock units shall vest in four equal quarterly installments over the one-year period following the grant date, subject to the reporting person's continued service. The shares underlying any vested restricted stock units shall be released to the reporting person on June 1, 2024. |
Filing footnotes · ownership attribution and instrument terms
F1: The securities awarded are in the form of restricted stock units issued pursuant to the issuer's 2020 Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of issuer common stock. The restricted stock units shall vest in four equal quarterly installments over the one-year period following the grant date, subject to the reporting person's continued service. The shares underlying any vested restricted stock units shall be released to the reporting person on June 1, 2024.
MESA LABORATORIES INC /CO/
Report date September 09, 2026 · Filed September 11, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock Units - 4SEC Table II · derivative / convertible security | Direct | 2,423 |
Reported balance
After 2026-09-09 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-09-09 · Grant · Acquired 2,423 · Balance 2,423 F1: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock F2: RSUs that vest on September 9, 2027 F3: Not Applicable |
Filing footnotes · ownership attribution and instrument terms
F1: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock
F2: RSUs that vest on September 9, 2027
F3: Not Applicable
MYRIAD GENETICS INC
Report date September 30, 2019 · Filed October 01, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 522,216 |
Ending reported balance
After 2019-09-30 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2019-09-30 · Disposition to issuer · Disposed 8,727 · Balance 540,511 F1: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of performance stock units granted to the reporting person. Row 2 · 2019-09-30 · Disposition to issuer · Disposed 18,295 · Balance 522,216 F1: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of performance stock units granted to the reporting person. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of performance stock units granted to the reporting person.
SERA PROGNOSTICS, INC.
Report date July 10, 2026 · Filed July 14, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 44,379 |
Ending reported balance
After 2026-07-10 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-07-10 · Grant · Acquired 42,404 · Balance 42,404 F1: Each share is represented by a restricted stock unit ("RSU") granted pursuant to the issuer's Non-Employee Director Compensation Policy and its 2021 Equity Incentive Plan. These RSUs vest in three annual installments beginning with July 10, 2027, subject to the Reporting Person continuing to provide services to the issuer. Row 2 · 2026-07-10 · Grant · Acquired 1,975 · Balance 44,379 F2: Each share is represented by an additional RSU granted by the Board of Directors. These RSUs vest on the earlier of July 10, 2027 or the date of the issuer's next Annual Meeting of Stockholders, subject to the Reporting Person continuing to provide services to the issuer. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.97 · Expires 2036-07-10 | Direct | 62,766 |
Reported balance
After 2026-07-10 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-07-10 · Grant · Acquired 62,766 · Balance 62,766 F3: Consists of stock options granted pursuant to the issuer's Non-Employee Director Compensation Policy and its 2021 Equity Incentive Plan. These stock options vest over three years as follows: 1/36 of the original grant amount vests in monthly installments for three years following the grant date, subject to the Reporting Person continuing to provide services to the issuer. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.97 · Expires 2036-07-10 | Direct | 3,037 |
Reported balance
After 2026-07-10 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-07-10 · Grant · Acquired 3,037 · Balance 3,037 F4: These stock options vest over one year as follows: 1/12 of the original grant amount vests in monthly installments for one year following the grant date; provided, however, that the stock options shall be fully vested on the earlier of the first anniversary of the grant date or the date of the issuer's next Annual Meeting of Stockholders, subject to the Reporting Person continuing to provide services to the issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: Each share is represented by a restricted stock unit ("RSU") granted pursuant to the issuer's Non-Employee Director Compensation Policy and its 2021 Equity Incentive Plan. These RSUs vest in three annual installments beginning with July 10, 2027, subject to the Reporting Person continuing to provide services to the issuer.
F2: Each share is represented by an additional RSU granted by the Board of Directors. These RSUs vest on the earlier of July 10, 2027 or the date of the issuer's next Annual Meeting of Stockholders, subject to the Reporting Person continuing to provide services to the issuer.
F3: Consists of stock options granted pursuant to the issuer's Non-Employee Director Compensation Policy and its 2021 Equity Incentive Plan. These stock options vest over three years as follows: 1/36 of the original grant amount vests in monthly installments for three years following the grant date, subject to the Reporting Person continuing to provide services to the issuer.
F4: These stock options vest over one year as follows: 1/12 of the original grant amount vests in monthly installments for one year following the grant date; provided, however, that the stock options shall be fully vested on the earlier of the first anniversary of the grant date or the date of the issuer's next Annual Meeting of Stockholders, subject to the Reporting Person continuing to provide services to the issuer.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 30, 2017 Filed Oct 3, 2017 20:43 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Disposition to issuerCommon Stock | 19,367 | $36.18 | $700,698.06 |
DisclosureSEC source: 0001352413-17-000006 · edgardoc.xml · nonDerivative · entry 1 Capone Mark Christopher · CIK 0001352413 · President & C.E.O. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 341,413 F1 · kind: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of performance stock units granted to the reporting person. Read SEC document |
| September 17, 2017 Filed Sep 19, 2017 21:20 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Disposition to issuerCommon Stock | 11,671 | $33.05 | $385,726.55 |
DisclosureSEC source: 0001352413-17-000004 · edgardoc.xml · nonDerivative · entry 1 Capone Mark Christopher · CIK 0001352413 · President & C.E.O. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 360,780 F1 · kind: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of performance stock units granted to the reporting person. Read SEC document |
| September 13, 2017 Filed Sep 15, 2017 20:31 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | GrantCommon Stock | 165,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001352413-17-000002 · edgardoc.xml · nonDerivative · entry 1 Capone Mark Christopher · CIK 0001352413 · President & C.E.O. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 372,451 F1 · kind: Consists of performance stock units granted pursuant to the Company?s 2010 Employee, Director and Consultant Equity Incentive Plan. Performance stock units initially granted on September 14, 2016, subject to accomplishment of pre-determined financial performance requirements. On September 13, 2017, the Compensation Committee determined the final award amount based on the accomplishment of the applicable financial performance requirements. Each performance stock unit represents a contingent right to receive one share of the Company?s common stock,and vests 25% on September 30, 2017, 25% on September 30, 2018, 25% on September 30, 2019, and 25% on September 30, 2020. Read SEC document |
| September 30, 2016 Filed Oct 3, 2016 21:45 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Disposition to issuerCommon Stock | 9,238 | $20.58 | $190,118.04 |
DisclosureSEC source: 0001352413-16-000012 · edgardoc.xml · nonDerivative · entry 1 Capone Mark Christopher · CIK 0001352413 · President & C.E.O. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 207,451 F1 · kind: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of performance stock units granted to the reporting person. Read SEC document |
| September 17, 2016 Filed Sep 20, 2016 12:16 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Disposition to issuerCommon Stock | 8,042 | $20.92 | $168,238.64 |
DisclosureSEC source: 0001352413-16-000010 · edgardoc.xml · nonDerivative · entry 1 Capone Mark Christopher · CIK 0001352413 · President & C.E.O. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 216,689 F1 · kind: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of performance stock units granted to the reporting person. Read SEC document |
| September 14, 2016 Filed Sep 16, 2016 17:30 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | GrantCommon Stock | 78,705 | $0.00 | $0.00 |
DisclosureSEC source: 0001352413-16-000008 · edgardoc.xml · nonDerivative · entry 1 Capone Mark Christopher · CIK 0001352413 · President & C.E.O. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 224,731 F1 · kind: Consists of performance stock units granted pursuant to the Company?s 2010 Employee, Director and Consultant Equity Incentive Plan. Each performance stock unit represents a contingent right to receive one share of the Company?s common stock,and vests 25% on September 30, 2016, 25% on September 30, 2017, 25% on September 30, 2018, and 25% on September 30, 2019. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.